News | May 18, 2026
Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
This marks the first partnership between Pfizer and Cipla in India
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Subscribe To Our Newsletter & Stay Updated
